Epidemiology and costs associated with genital warts in Canada

Sexually Transmitted Infections

Volumn 85, Issue 2, 2009, Pages 111-115

  Marra, F ^a,b   Ogilvie, G ^a,b   Colley, L ^a,c   Kliewer, E ^d,e,f   Marra, C A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^d CANCERCARE MANITOBA   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; PODOPHYLLOTOXIN; SALICYLIC ACID;

ADULT; ARTICLE; CANADA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST; DATA BASE; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICAL RECORD; OUTPATIENT DEPARTMENT; PODOPHYLLUM; PRIORITY JOURNAL;

ADULT; BRITISH COLUMBIA; CONDYLOMATA ACUMINATA; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; YOUNG ADULT;

EID: 65649086009     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2008.030999     Document Type: Article

References (29)

1. Walboomers J. M. Jacobs M. V. Manos M. M. et al. Human papillomavirus is a necessary cause of invasive cancer worldwide. J Pathol 1999; 189: 12-19.
2. Jansen K. U. Shaw A. R. Human papillomavirus vaccines and prevention of cervical cancer. Ann Rev Med 2004; 55: 319-31.
3. Bosch F. X. Lorincz A. Muñoz N. et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
4. Koutsky L. A. Galloway D. A. Holmes K. K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10: 122-63.
5. Merck Frosst Canada Ltd. Gardasil™ (Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) product monograph, 26 June 2007. http://www.merckfrosst.ca/mfcl/en/corporate/products/gardasil.html (accessed Nov. 2008).
6. GlaxoSmithKline. Cervarix™ (Human papillomavirus (types 16, 18) recombinant adjuvanted, adsorbed vaccine) product monograph, September 2007. http://www.gsk.com (accessed Nov. 2008).
7. Sanders G. D. Taira A. V. Cost effectiveness of a potential vaccine for Human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
8. Kulasingam S. L. Myers E. R. Potential health and economic impact of adding human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9.
9. Goldie S. J. Kohli M. Grima D. et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15.
10. Brisson M. Van de Velde N. De Wals P. et al. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-408.
11. Kulasingam S. Connelly L. Conway E. et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sexual Health 2007; 4: 165-75.
12. Taira A. V. Neukermans C. P. Sanders G. D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-23.
13. Elbasha E. H. Dasbach E. J. Insinga R. P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41.
14. Insinga R. P. Dasbach E. J. Elbasha E. H. et al. Cost-effectiveness of quadrivalent human papillomavirus (HPV) in Mexico: a transmission dynamic model-based evaluation. Vaccine 2007; 26: 128-39.
15. Kim J. J. Andres-Beck B. Goldie S. J. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007; 97: 1322-8.
16. Kliewer E. V. Demers A. A. Elliott L. et al. Twenty year trends (1985-2004) in the incidence and prevalence of anogenital warts in Manitoba. Winnipeg: Cancercare Manitoba, 2008: 45.
17. Butler JRG, Kliewer E. V. Demers A. A. et al. The cost of treating anogenital warts in Manitoba, Canada. Poster presented at the 24th International Papillomavirus Conference; 3-9 November 2007, Beijing, China.
18. Ministry of Health Services. Medical Services Plan. Information Resource Management Branch, Knowledge Management and Technology Division. Ministry of Health Services.http://www.gov.bc.ca/health/ (accessed Nov. 2008).
19. Williams J. I. Young W. Inventory of studies on the accuracy of Canadian health administrative databases (publication no 96-03-TR). Toronto: Institute for Clinical Evaluative Sciences, 1996.
20. Health Protection Agency (UK). Human papillomavirus (HPV) -cervical cancer and genital warts. Genitourinary surveillance data, http://www.hpa.org. uk/infections/topics-az/hiv-and-sti/Stats/STIs/warts/statistics.htm (accessed 5 March 2008).
21. Singhal P. K. Schabert V. Insinga R. P. et al. The incidence and healthcare cost of genital warts in a commercially insured population in the United States. Poster presented at the 24th International Papillomavirus Conference. 3-9 November 2007, Beijing, China.
22. Conway E. L. Stein A. N. Britt H. et al. Genital warts and associated health care use in general practice in Australia. 24th International Papillomavirus Conference. 3-9 November 2007, Beijing, China [abstract]
23. Insinga R. P. Dasbach E. J. Myers E. R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003; 36: 1397-403.
24. Morrow A. Chuah J. Conway E. L. et al. Patterns of treatment and resource utilization in the management of genital warts in Australian sexual health clinics. 24th International Papillomavirus Conference. 3-9 November 2007, Beijing, China [abstract]
25. Johnston V. J. Britt H. Pan Y. et al. The management of sexually transmitted infections by Australian practitioners. Sex Transm Infect 2004; 80: 212-15.
26. Lacey C. J. Lowndes C. M. Shah K. V. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24 (Suppl 3): 535-41.
27. BC Cancer Agency. Cervical cancer screening programme, 2006. http://www.bccancer.bc.ca/PPI/screening/cervical (accessed 13 May 2008).
28. McTaggart-Cowan H. M. Marra C. A. Yang Y. et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res 2008; 17: 453-62.
29. Marra C. A. Cibere J. Tsuyuki R. T. et al. Improving osteoarthritis detection in the community: pharmacist identification of new, diagnostically confirmed osteoarthritis. Arthritis Rheum 2007; 15: 1238-44.